언어 선택

Monoamine oxidase B

Monoamine oxidase B 분자 정보

영어 이름	Monoamine oxidase B	시판 약물 수	3
임상 약물 수	13	표적 별명	EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4
최고 연구 개발 단계	Approved

영어 이름	Monoamine oxidase B
표적 별명	EC:1.4.3.4，EC 1.4.3，MAOB，Amine oxidase [flavin-containing] B，Monoamine Oxidase B，Monoamine Oxidase Type B，MAO-B，Adrenalin Oxidase，Tyramine Oxidase，MAO， Platelet，MAO， Brain，EC 1.4.3.4
시판 약물 수	3
임상 약물 수	13
최고 연구 개발 단계	Approved

Monoamine oxidase B 제품 목록

속성
Protein (1)
제품 라이브러리
온라인 (1)
종
Human (1)
태그
His Tag (1)
마커
Unconjugated (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
MAB-H5547	Human	InsectCells	Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme)

총 수량1

Monoamine oxidase B분자 배경

Monoamine Oxidase Type B (MAOB) is an enzyme located in the outer mitochondrial membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the breakdown of dopamine in the brain. MAOB inhibitors, that reduces dopamine turnover, are in clinical use for the treatment of Parkinson's disease (PD).

Monoamine oxidase B분자 별명

MAOB, MAO-B,Monoamine Oxidase B,Monoamine oxidase type B

라이선싱 협력

프로젝트 이름	약물 유형	치료 영역	적응증	단계	권리 지역
Reversible MAOB Inhibitor	Small molecule	Neurological disease	Parkinson's disease	Phase I	Global

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate	P2B-001	Phase 3 Clinical	Pharma Two B Ltd	Parkinson Disease	상세
Vafidemstat	ORY-2001	Phase 2 Clinical	Oryzon Genomics Sa	Alzheimer Disease; Borderline Personality Disorder; Kabuki syndrome; Schizophrenia	상세
J-147	J-147	Phase 2 Clinical	Salk Institute	Alzheimer Disease; Ischemic Stroke	상세
Tisolagiline	KDS2010; KDS-2010	Phase 2 Clinical	NeuroBiogen	Alzheimer Disease; Cognitive Dysfunction; Dementia; Obesity; Overweight	상세
Rasagiline transdermal patch (Teikoku Pharma)		Phase 1 Clinical	Teikoku Pharma	Parkinson Disease	상세
SKL-PD	YKP-10461; SKL-PD	Phase 1 Clinical	SK Biopharmaceuticals Co Ltd	Parkinson Disease	상세
18F-FCOB04	18F-FCOB04; 18F-FCOB-04	Phase 1 Clinical	Peking Union Medical College Hospital	Neurodegenerative Diseases	상세
LNTH-2511		Phase 1 Clinical	Lantheus Holdings Inc	Neuroinflammatory Diseases	상세
Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma)		Phase 1 Clinical	Zhejiang Jingxin Pharmaceutical Co Ltd	Parkinson Disease	상세
Rasagiline Mesylate Sublingual membrane(Shanghai Shangyao Zhongxi Pharma)		Phase 1 Clinical	Shanghai Shangyao Zhongxi Pharmaceutical Co Ltd	Parkinson Disease	상세
Rasagiline Mesylate Transdermal Patch(world leader)		Phase 1 Clinical	Guizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd	Parkinson Disease	상세
HEC-122505MsOH	HEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOH	Phase 1 Clinical	Guangdong Dongyangguang Pharmaceutical Co Ltd	Parkinson Disease	상세
18F-SMBT-1	18F-SMBT-1; 18-F-SMBT-1	Clinical	Tohoku University		상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Rasagiline Mesylate	Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012	Approved	Teva	Azilect, Agilect	EU	Parkinson Disease	Teva Bv	2005-02-21	Alzheimer Disease; Dementia; Multiple System Atrophy; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Supranuclear Palsy, Progressive; Synucleinopathies	상세
Selegiline Hydrochloride	FPF-1100; E-250 (free base)	Approved	Sanofi	FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline	Mainland China	Parkinson Disease	Chinoin Pharmaceutical And Chemical Works Co Ltd	1989-06-05	Amphetamine-Related Disorders; Borderline Personality Disorder; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder, Major; HIV Infections; Marijuana Abuse; Parkinson Disease; Schizophrenia; Tobacco Use Cessation; Tobacco Use Disorder	상세
Safinamide Mesylate	PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743	Approved	Newron Pharmaceutical	Xadago, Equfina	EU	Parkinson Disease	Zambon Spa	2015-02-23	Dyskinesia, Drug-Induced; Hepatic Insufficiency; Multiple System Atrophy; Parkinson Disease; Renal Insufficiency	상세